Company: HUM
Filing Date: 2025-03-03
Form Type: 424B5
Source: 0001628280-25-009237
Chunk: 0

Company: HUMANA INC
Filing Date: 2025-03-03
Form: 424B5
Chunk 0
---
#### Filed Pursuant to Rule 424(b)(5)

#### Registration No. 333-277734
The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

### SUBJECT TO COMPLETION
<div align='center'>PRELIMINARY PROSPECTUS SUPPLEMENT DATED MARCH 3, 2025</div>

#### Prospectus Supplement

#### , 2025
(To Prospectus dated March 7, 2024)

<div align='center'>$</div>

#### Humana Inc.
<div align='center'>$ % Senior Notes due 20

$ % Senior Notes due 20</div>

The 20 notes will bear interest at % per year and the 20 notes will bear interest at % per year. Interest on the 20 notes and the 20 notes will be payable on and of each year, beginning on , 2025. The 20 notes will mature on , 20 and the 20 notes will mature on , 20 . We refer to the 20 notes and the 20 notes collectively as the notes. Interest on the 20 notes and the 20 notes will accrue from , 2025. At our option, we may redeem the notes, in whole or in part, before their maturity date at the applicable redemption prices described in this prospectus supplement under the caption “Description of the Notes—Optional Redemption.” If a change of control triggering event as described in this prospectus supplement occurs, unless we have exercised our option to redeem the notes, we will be required to offer to repurchase the notes at the price described in this prospectus supplement under the caption “Description of the Notes—Offer to Repurchase Upon Change of Control Triggering Event.”

The notes will be our unsecured senior obligations and will rank equally with all of our other existing and future unsecured senior indebtedness.

Investing in the notes involves risks that are described in the “

#### Risk Factors

#### ” sections beginning on page

#### S- 4
of this prospectus supplement and in other documents incorporated by reference in this prospectus supplement and the accompanying prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus